CorrectSequence Therapeutics
Tracked across 2 events · 14 articles · First seen Jun 02, 2026 · Last active Sep 08, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Tech
Impact: CorrectSequence Therapeutics has reported positive 15-month follow-up data for its CS-206 therapy, demonstrating its efficacy and safety in treating sickle cell disease. This success enhances the company's reputation and potential for commercialization.
Jun 02, 2026 · 8 articles
Tech
On September 7, 2026, CorrectSequence Therapeutics (Correctseq) announced the publication of clinical research in Cell Stem Cell demonstrating that its transformer Base Editor (tBE) based therapies, CS-101 and CS-206, achieved consistent efficacy and safety in…
Impact: Developer of the tBE platform and therapies CS-101/CS-206; positive clinical results enhance its pipeline value and competitive position.
Jul 20, 2026 · 6 articles
90
CorrectSequence Therapeutics published clinical researchtBE Base Editing Therapy...
80
CorrectSequence Therapeutics treated patientstBE Base Editing Therapy...
70
CorrectSequence Therapeutics completed Phase ItBE Base Editing Therapy...
ERGEN INTELLIGENCE
Track CorrectSequence Therapeutics live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard